Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10742309 | PMC |
| http://dx.doi.org/10.3390/cancers15245885 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Morning administration of anthracyclines is associated with a lower risk of cancer therapy-related cardiac dysfunction.
Eur Heart J Open
September 2025
Department of Cardiology, Division of Heart and Lungs, University Medical Centre Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
Aims: Pre-clinical studies point towards an administration time-dependency of anthracycline-induced cancer therapy-related cardiac dysfunction (CTRCD). This retrospective study aimed to investigate the association between time-of-day of AC administration and CTRCD.
Methods And Results: Patients from two cardio-oncology outpatient clinics, treated with ACs for any malignancy, were included.
Natural Products From Traditional Chinese Medicine: Potential Therapeutic Agents in Cancer Therapy-Induced Cardiotoxicity.
Drug Des Devel Ther
September 2025
Department of Cardiology, Qidong People's Hospital/Qidong Liver Cancer Institute/Affiliated Qidong Hospital of Nantong University, Qidong, Jiangsu, 226200, People's Republic of China.
Cancer therapy-induced cardiotoxicity (CTIC) is a serious and increasingly recognized cause of death and disability among cancer survivors. It frequently necessitates the withdrawal or dose reduction of effective anticancer drugs, limiting therapeutic options and affecting patient outcomes. While CTIC poses a major health risk, the precise cellular and molecular mechanisms responsible for this toxicity remain elusive, which complicates the development of preventive and therapeutic strategies.
View Article and Find Full Text PDFHER2-targeted therapies and cardiotoxicity: From major concern to manageable risk.
Curr Probl Cardiol
September 2025
Internal Medicine Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Electronic address:
HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, but their potential for cardiotoxicity remains a critical clinical concern. Early trials reported high rates of cardiac dysfunction, particularly with concomitant anthracycline use, prompting the development of intensive cardiac monitoring strategies. However, emerging evidence suggests that most cardiotoxic events are asymptomatic, reversible, and rarely require permanent treatment discontinuation, particularly with newer agents such as antibody-drug conjugates.
View Article and Find Full Text PDFCluster analysis of hotspots and research trends of epirubicin-induced cardiotoxicity: a bibliometric study.
Front Pharmacol
August 2025
Medical Oncology of The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China.
Background: Epirubicin, a widely used anthracycline, effectively treats various cancers but poses a high risk of cardiotoxicity, leading to heart failure and myocardial dysfunction. This study conducts a cluster analysis to map global research trends in epirubicin-induced cardiotoxicity.
Methods: A literature search was conducted using the Web of Science Core Collection database.
Cardiac Adaptation in Lupus: A Case of Massive Pericardial Effusion With Preserved Hemodynamics.
Cureus
July 2025
Cardiology, Saint Michael's Medical Center/New York Medical College, Newark, USA.
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease; cardiac involvement is a recognized complication, with pericardial effusion being one of the most frequent manifestations. Here, we present a patient with massive pericardial effusion in a known SLE patient without hemodynamic instability, highlighting concepts of pericardial compliance and physiological adaptation in autoimmune disease. We present a case of a 33-year-old female with a known history of SLE who presented with progressively worsening pleuritic chest pain over three weeks.
View Article and Find Full Text PDF